Within-host whole genome analysis of an antibiotic resistant Pseudomonas aeruginosa strain sub-type in cystic fibrosis

A Pseudomonas aeruginosa AUST-02 strain sub-type (M3L7) has been identified in Australia, infects the lungs of some people with cystic fibrosis and is associated with antibiotic resistance. Multiple clonal lineages may emerge during treatment with mutations in chromosomally encoded antibiotic resistance genes commonly observed. Here we describe the within-host diversity and antibiotic resistance of M3L7 during and after antibiotic treatment of an acute pulmonary exacerbation using whole genome sequencing and show both variation and shared mutations in important genes. Eleven isolates from an M3L7 population (n = 134) isolated over 3 months from an individual with cystic fibrosis underwent whole genome sequencing. A phylogeny based on core genome SNPs identified three distinct phylogenetic groups comprising two groups with higher rates of mutation (hypermutators) and one non-hypermutator group. Genomes were screened for acquired antibiotic resistance genes with the result suggesting that M3L7 resistance is principally driven by chromosomal mutations as no acquired mechanisms were detected. Small genetic variations, shared by all 11 isolates, were found in 49 genes associated with antibiotic resistance including frame-shift mutations (mexA, mexT), premature stop codons (oprD, mexB) and mutations in quinolone-resistance determining regions (gyrA, parE). However, whole genome sequencing also revealed mutations in 21 genes that were acquired following divergence of groups, which may also impact the activity of antibiotics and multi-drug efflux pumps. Comparison of mutations with minimum inhibitory concentrations of anti-pseudomonal antibiotics could not easily explain all resistance profiles observed. These data further demonstrate the complexity of chronic and antibiotic resistant P. aeruginosa infection where a multitude of co-existing genotypically diverse sub-lineages might co-exist during and after intravenous antibiotic treatment.

[1]  T. Köhler,et al.  Characterization of MexT, the Regulator of the MexE-MexF-OprN Multidrug Efflux System of Pseudomonas aeruginosa , 1999, Journal of bacteriology.

[2]  S. Lory,et al.  Complete genome sequence of Pseudomonas aeruginosa PAO 1 , an opportunistic pathogen , 2000 .

[3]  T. Nakae,et al.  Variation of the mexT gene, a regulator of the MexEF-oprN efflux pump expression in wild-type strains of Pseudomonas aeruginosa. , 2000, FEMS microbiology letters.

[4]  S. Lory,et al.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen , 2000, Nature.

[5]  A. Oliver,et al.  High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. , 2000, Science.

[6]  M. Dodd,et al.  Increased treatment requirements of patients with cystic fibrosis who harbour a highly transmissible strain of Pseudomonas aeruginosa , 2002, Thorax.

[7]  B. Ramsey,et al.  Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. , 2003, Chest.

[8]  P. Robinson,et al.  Pseudomonas Cross-Infection from Cystic Fibrosis Patients to Non-Cystic Fibrosis Patients: Implications for Inpatient Care of Respiratory Patients , 2003, Journal of Clinical Microbiology.

[9]  S. Bell,et al.  Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units , 2004, European Respiratory Journal.

[10]  Matthew Berriman,et al.  ACT: the Artemis comparison tool , 2005, Bioinform..

[11]  David A. D'Argenio,et al.  Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[12]  E. Birney,et al.  Velvet: algorithms for de novo short read assembly using de Bruijn graphs. , 2008, Genome research.

[13]  R. Goering,et al.  Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  P. Nordmann,et al.  Extended-Spectrum Cephalosporinases in Pseudomonas aeruginosa , 2009, Antimicrobial Agents and Chemotherapy.

[15]  A. Hawkins.  Cystic Fibrosis Trust , 2009 .

[16]  N. Gotoh,et al.  Classification of OprD sequence and correlation with antimicrobial activity of carbapenem agents in Pseudomonas aeruginosa clinical isolates collected in Japan , 2009, Microbiology and immunology.

[17]  N. Perna,et al.  progressiveMauve: Multiple Genome Alignment with Gene Gain, Loss and Rearrangement , 2010, PloS one.

[18]  Lucian Ilie,et al.  SHRiMP2: Sensitive yet Practical Short Read Mapping , 2011, Bioinform..

[19]  P. Cullinan,et al.  Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007 , 2011, BMJ : British Medical Journal.

[20]  Nicola K. Petty,et al.  BLAST Ring Image Generator (BRIG): simple prokaryote genome comparisons , 2011, BMC Genomics.

[21]  M. Brockhurst,et al.  Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections. , 2011, American journal of respiratory and critical care medicine.

[22]  David S. Wishart,et al.  PHAST: A Fast Phage Search Tool , 2011, Nucleic Acids Res..

[23]  Andreas Dötsch,et al.  Quantitative Contributions of Target Alteration and Decreased Drug Accumulation to Pseudomonas aeruginosa Fluoroquinolone Resistance , 2012, Antimicrobial Agents and Chemotherapy.

[24]  A. Smyth,et al.  Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis☆ , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[25]  T. Coenye,et al.  Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorum-sensing inhibitors against Pseudomonas aeruginosa in an intraperitoneal foreign-body infection mouse model , 2012 .

[26]  S. Rasmussen,et al.  Identification of acquired antimicrobial resistance genes , 2012, The Journal of antimicrobial chemotherapy.

[27]  J. Fothergill,et al.  Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections , 2012, European Respiratory Journal.

[28]  Songnian Hu,et al.  EvolView, an online tool for visualizing, annotating and managing phylogenetic trees , 2012, Nucleic Acids Res..

[29]  J. Elborn,et al.  Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. , 2012, Chest.

[30]  J. Stockman.  Infection With Transmissible Strains of Pseudomonas aeruginosa and Clinical Outcomes in Adults With Cystic Fibrosis , 2012 .

[31]  M. Elkins,et al.  Shared Pseudomonas aeruginosa genotypes are common in Australian cystic fibrosis centres , 2012, European Respiratory Journal.

[32]  G. Smith,et al.  Genomic Variation among Contemporary Pseudomonas aeruginosa Isolates from Chronically Infected Cystic Fibrosis Patients , 2012, Journal of bacteriology.

[33]  Andrew C. Pawlowski,et al.  The Comprehensive Antibiotic Resistance Database , 2013, Antimicrobial Agents and Chemotherapy.

[34]  R. Kassen,et al.  Evolutionary genomics of epidemic and nonepidemic strains of Pseudomonas aeruginosa , 2013, Proceedings of the National Academy of Sciences.

[35]  S. Molin,et al.  Genome Analysis of a Transmissible Lineage of Pseudomonas aeruginosa Reveals Pathoadaptive Mutations and Distinct Evolutionary Paths of Hypermutators , 2013, PLoS genetics.

[36]  Derrick E. Wood,et al.  Kraken: ultrafast metagenomic sequence classification using exact alignments , 2014, Genome Biology.

[37]  Andrea M. Smania,et al.  Coexistence and Within-Host Evolution of Diversified Lineages of Hypermutable Pseudomonas aeruginosa in Long-term Cystic Fibrosis Infections , 2014, PLoS genetics.

[38]  Torsten Seemann,et al.  Prokka: rapid prokaryotic genome annotation , 2014, Bioinform..

[39]  Alexandros Stamatakis,et al.  RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies , 2014, Bioinform..

[40]  S. Lory,et al.  Structural and Functional Characterization of Pseudomonas aeruginosa Global Regulator AmpR , 2014, Journal of bacteriology.

[41]  S. Bell,et al.  A comparison of two informative SNP-based strategies for typing Pseudomonas aeruginosa isolates from patients with cystic fibrosis , 2014, BMC Infectious Diseases.

[42]  Jacques Corbeil,et al.  The Resistome of Pseudomonas aeruginosa in Relationship to Phenotypic Susceptibility , 2014, Antimicrobial Agents and Chemotherapy.

[43]  Brian D. Ondov,et al.  The Harvest suite for rapid core-genome alignment and visualization of thousands of intraspecific microbial genomes , 2014, Genome Biology.

[44]  R. S. Soares Magalhaes,et al.  The social network of cystic fibrosis centre care and shared Pseudomonas aeruginosa strain infection: a cross-sectional analysis. , 2015, The Lancet. Respiratory medicine.

[45]  S. Bell,et al.  Genotypic Diversity within a Single Pseudomonas aeruginosa Strain Commonly Shared by Australian Patients with Cystic Fibrosis , 2015, PloS one.

[46]  Justin Zobel,et al.  Bandage: interactive visualization of de novo genome assemblies , 2015, bioRxiv.

[47]  M. Brockhurst,et al.  Divergent, coexisting Pseudomonas aeruginosa lineages in chronic cystic fibrosis lung infections. , 2015, American journal of respiratory and critical care medicine.

[48]  S. Donaldson,et al.  Selective Sweeps and Parallel Pathoadaptation Drive Pseudomonas aeruginosa Evolution in the Cystic Fibrosis Lung , 2015, mBio.

[49]  J. Kitzman,et al.  Regional Isolation Drives Bacterial Diversification within Cystic Fibrosis Lungs. , 2015, Cell host & microbe.

[50]  Yongwook Choi,et al.  PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels , 2015, Bioinform..

[51]  Andrew J. Page,et al.  Roary: rapid large-scale prokaryote pan genome analysis , 2015, bioRxiv.

[52]  S. Molin,et al.  Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis , 2014, Nature Genetics.

[53]  Jacqueline A. Keane,et al.  Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome sequences using Gubbins , 2014, Nucleic acids research.

[54]  L. Piddock.  Assess drug-resistance phenotypes, not just genotypes , 2016, Nature Microbiology.

[55]  Christopher T. Campbell,et al.  New Inhaled Antimicrobial Formulations for Use in the Cystic Fibrosis Patient Population , 2016, The Annals of pharmacotherapy.

[56]  Christina A. Sutherland,et al.  In vitro Activity of Ceftolozane/Tazobactam Alone or with an Aminoglycoside Against Multi-Drug-Resistant Pseudomonas aeruginosa from Pediatric Cystic Fibrosis Patients , 2016, Infectious Diseases and Therapy.

[57]  S. McColley,et al.  Aminoglycoside resistance of Pseudomonas aeruginosa in cystic fibrosis results from convergent evolution in the mexZ gene , 2016, Thorax.